-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-0728 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0728 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0728 in Breast Cancer Drug Details: TAS-0728 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-114 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-114 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-114 in Metastatic Breast Cancer Drug Details: TAS-114 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Non-Small Cell Lung Cancer Drug Details: TAS-2940 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Solid Tumor Drug Details: TAS-2940 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-0728 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0728 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0728 in Non-Small Cell Lung Cancer Drug Details: TAS-0728 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: TAS-2940...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Gastric Cancer Drug Details: Monoclonal antibody is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sonpiretigene Isteparvovec in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sonpiretigene Isteparvovec in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sonpiretigene Isteparvovec in Juvenile Macular Degeneration (Stargardt Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Pancreatic Ductal Adenocarcinoma Drug Details: Zenocutuzumab (MCLA-128) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Details:...